📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Kalpataru Reports 23% Growth in 9M Pre-Sales to ₹3,447 Cr; Q3 Pre-Sales Dip 14% YoY
Kalpataru Limited reported a mixed performance for Q3 FY26, with quarterly pre-sales declining by 14% YoY to ₹870 crore. However, the cumulative nine-month performance remains strong, with pre-sales growing 23% YoY to ₹3,447 crore. Collections showed robust growth, increasing 17% in Q3 to ₹1,101 crore and 30% for the nine-month period to ₹3,409 crore. The overall nine-month trajectory suggests healthy demand and improved cash flow despite a quarterly dip in sales bookings.
Key Highlights
9M FY26 pre-sales increased by 23% YoY to ₹3,447 crore from ₹2,807 crore
9M FY26 collections grew significantly by 30% YoY to ₹3,409 crore
Q3 FY26 pre-sales saw a 14% YoY decline, falling to ₹870 crore from ₹1,008 crore
Q3 FY26 collections remained strong at ₹1,101 crore, up 17% YoY from ₹943 crore
💼 Action for Investors
Investors should focus on the strong cumulative nine-month growth and improved cash flow through collections rather than the quarterly sales dip. Monitor the upcoming full earnings report to understand the reasons behind the Q3 pre-sales decline.
Dr. Lal PathLabs Launches SOVAAKA Wellness Centre to Expand into Premium Preventive Care
Dr. Lal PathLabs has launched SOVAAKA, a premium wellness center in Gurugram, marking its entry into the high-growth preventive healthcare segment. The facility integrates advanced diagnostics like 1.5T MRI and genetic testing with AI-driven insights to offer personalized health programs. This strategic move aims to transition the company from disease detection to predictive wellness, targeting higher-margin lifestyle disease management. As of March 2025, the company operates 298 labs and over 6,607 service centers, providing a strong foundation for scaling such premium initiatives.
Key Highlights
Launched SOVAAKA in Gurugram, a next-generation wellness center blending science and AI technology.
Equipped with high-end diagnostic tools including 1.5T MRI, low-dose CT, and DEXA scanning.
Offers specialized, doctor-designed programs like Eterna for women and Vita for men.
Strategic focus on the growing preventive health market to address rising Non-Communicable Diseases.
Company network includes 298 clinical labs and 12,365 pick-up points as of March 31, 2025.
💼 Action for Investors
This expansion into premium wellness is a positive move to increase average revenue per patient; investors should watch for further rollouts of this format in other metros.
Kalpataru Ltd Seeks Shareholder Approval for Material Related Party Transactions
Kalpataru Limited has issued a postal ballot notice to seek shareholder approval for several material related party transactions (RPTs). The proposed resolutions include transactions with its subsidiaries, Kalpataru Properties (Thane) and Agile Real Estate Dev, as well as various promoter group entities and the Managing Director, Mr. Parag M. Munot. Notably, one resolution involves providing financial assistance via Inter Corporate Deposits to its subsidiary, Agile Real Estate Dev. The e-voting period is set for January 03 to February 01, 2026, with results to be announced by February 03, 2026.
Key Highlights
Postal ballot notice dispatched on January 02, 2026, for three ordinary resolutions regarding material RPTs.
Resolution 2 specifically seeks approval for extending financial assistance via Inter Corporate Deposits to subsidiary Agile Real Estate Dev.
Resolution 3 involves transactions with multiple promoter group entities and the Managing Director, Mr. Parag M. Munot.
The remote e-voting window is open for 30 days, starting January 03, 2026, and concluding on February 01, 2026.
The cut-off date for determining shareholder eligibility for voting was Friday, December 26, 2025.
💼 Action for Investors
Investors should carefully review the explanatory statement in the postal ballot notice to assess the terms and arm's-length nature of these transactions, particularly the financial assistance to subsidiaries. Monitor the voting results on February 03, 2026, as these transactions can impact the company's cash flow and governance profile.
Kalpataru Ltd Receives ₹80.71 Crore GST Tax Demand and Penalty Order
Kalpataru Limited has received a formal tax demand order (DRC-07) from the CGST Mumbai authorities totaling ₹80.71 crores. The demand relates to alleged non-payment of GST on flats allotted to society members in exchange for development rights during FY 2018-19. The total amount includes ₹40.36 crores in tax and an equivalent ₹40.36 crores in penalties. The company plans to appeal the order and currently expects no material financial impact.
Key Highlights
Total tax demand and penalty amounting to ₹80,71,45,860.
Demand includes ₹40.36 crore in tax and ₹40.36 crore in penalties under Section 74 of the GST Act.
The dispute involves GST on flats provided to members for transfer of development rights in FY 2018-19.
The company intends to challenge the order before the Appellate Authority.
This matter was previously disclosed in the company's Red Herring Prospectus dated June 18, 2025.
💼 Action for Investors
Investors should monitor the progress of the appeal as an adverse final ruling could impact the company's cash flows, though the issue was previously disclosed in IPO documents.
Dr. Lal Path Labs Allots 8.37 Crore Bonus Shares in 1:1 Ratio
Dr. Lal Path Labs has completed the allotment of 8,37,75,510 bonus equity shares to eligible shareholders following its 1:1 bonus issue. The allotment was approved via a circular resolution on December 22, 2025, for shareholders on record as of December 19, 2025. This move doubles the company's total number of outstanding shares to 16,75,51,020. The paid-up equity share capital now stands increased at INR 167.55 crore, with the new shares ranking pari-passu with existing ones.
Key Highlights
Allotment of 8,37,75,510 fully paid-up bonus equity shares of face value INR 10 each.
Bonus issue executed in a 1:1 ratio for shareholders as of the December 19, 2025 record date.
Total paid-up equity capital increased from INR 83.77 crore to INR 167.55 crore.
Total number of equity shares outstanding increased to 16,75,51,020 shares.
New bonus shares rank pari-passu in all respects with existing equity shares.
💼 Action for Investors
Investors should note that while the number of shares in their portfolio has doubled, the stock price has been adjusted proportionally. No further action is required as the allotment is automatic for eligible shareholders.
Kalpataru Limited Withdraws Demerger Scheme for Project Yoganand
Kalpataru Limited has officially withdrawn its proposed Scheme of Arrangement for the demerger of Project Yoganand, located in Borivali, Mumbai. The project was initially intended to be transferred to its wholly-owned subsidiary, Kalpataru Residency Private Limited. The National Company Law Tribunal (NCLT), Mumbai Bench, has formally allowed this withdrawal as per its order dated November 25, 2025. This decision reverses the previous board approval, meaning the specific real estate asset will remain within the main listed entity's direct portfolio.
Key Highlights
Withdrawal of demerger scheme for Project Yoganand situated at Borivali, Mumbai
NCLT Mumbai Bench allowed the withdrawal of the application via order dated Nov 25, 2025
The project will no longer be transferred to the subsidiary Kalpataru Residency Private Limited
The Board of Directors had previously approved the withdrawal of the scheme on Nov 10, 2025
💼 Action for Investors
Investors should note that the asset remains with the parent company, maintaining the status quo on the balance sheet. Monitor for management commentary regarding the change in corporate restructuring strategy.
Dr. Lal PathLabs Increases Authorized Share Capital to INR 200 Crore
Dr. Lal PathLabs has received shareholder approval via postal ballot to significantly increase its authorized share capital. The limit has been raised from INR 107.96 crore to INR 200 crore, effectively doubling the company's capacity to issue new equity. This change involves a formal amendment to Clause V of the Memorandum of Association. While this is a regulatory enabling provision, it often serves as a precursor to future corporate actions such as bonus issues, rights issues, or equity-based fundraising.
Key Highlights
Authorized share capital increased from INR 107.96 crore to INR 200 crore.
Shareholder approval was obtained through a postal ballot concluded on December 07, 2025.
The new capital structure consists of 20,00,00,000 equity shares with a face value of INR 10 each.
Amendment to Clause V of the Memorandum of Association (MOA) has been officially implemented.
💼 Action for Investors
Investors should monitor the company for upcoming announcements regarding bonus issues or capital raises, as this move creates the necessary legal headroom for such actions.
Dr. Lal PathLabs Shareholders Approve Bonus Issue and New 2025 Employee Stock Unit Plan
Dr. Lal PathLabs has announced the successful passage of seven resolutions via postal ballot, most notably the issuance of bonus equity shares and an increase in authorized share capital. The 'Employee Restricted Stock Unit Plan 2025' was approved with 79.81% favor, although it faced significant institutional dissent with 51.5% of institutional votes cast against it. Additionally, shareholders cleared the path for secondary share acquisitions through a trust and a reduction in the 2022 options reserve. These approvals facilitate the company's capital restructuring and long-term incentive programs.
Key Highlights
Bonus Equity Shares issuance approved with 98.04% of total votes in favor.
Increase in Authorized Share Capital passed with a near-unanimous 99.84% majority.
New 'Employee Restricted Stock Unit Plan 2025' secured 79.81% support despite 51.5% institutional pushback.
Secondary acquisition of shares through a Trust route for ESOP implementation approved by 83.76% of voters.
Reduction of Options Reserve under the 2022 ESOP plan approved with 86.80% majority.
💼 Action for Investors
Investors should view the bonus issue as a positive move for share liquidity, though the high institutional dissent on the new ESOP plan suggests a need to monitor future management compensation and dilution.